Atara Biotherapeutics, Inc.

ATRA

$9.77

Name : Atara Biotherapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $88,029,384.00

EPSttm : -1.25

Atara Biotherapeutics, Inc.

$9.77

1.98%

$0.19

ATRA — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

9.18

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

-3.84

EPS This/Next Y

2.87

Price

9.83

Target Price

13.67

Analyst Recom

1.67

Performance Q

55.33

Upside

-415.3%

Beta

0.13

Ticker: ATRA

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-05-11	ATRA	8.61	N/A	N/A	0
2026-05-12	ATRA	9.81	N/A	N/A	0
2026-05-13	ATRA	10.58	N/A	N/A	0
2026-05-14	ATRA	9.51	N/A	N/A	0
2026-05-15	ATRA	9.65	N/A	N/A	0
2026-05-18	ATRA	9.2	N/A	N/A	0
2026-05-19	ATRA	9.44	N/A	N/A	0
2026-05-20	ATRA	9.48	N/A	N/A	0
2026-05-21	ATRA	9.48	N/A	N/A	0
2026-05-22	ATRA	9.86	N/A	N/A	0
2026-05-26	ATRA	9.79	N/A	N/A	0
2026-05-27	ATRA	10.67	N/A	N/A	0
2026-05-28	ATRA	11.12	N/A	N/A	0
2026-05-29	ATRA	10.53	N/A	N/A	0
2026-06-02	ATRA	10.13	N/A	N/A	0
2026-06-03	ATRA	9.63	N/A	N/A	0
2026-06-04	ATRA	10.4	N/A	N/A	0
2026-06-05	ATRA	9.93	N/A	N/A	0
2026-06-08	ATRA	9.52	N/A	N/A	0
2026-06-09	ATRA	9.91	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-05-11	ATRA	8.77	-106.2	-	-0.29
2026-05-12	ATRA	9.77	-106.2	-	-0.29
2026-05-13	ATRA	10.41	-106.2	-	-0.29
2026-05-14	ATRA	9.51	-106.2	-	-0.29
2026-05-15	ATRA	9.62	-106.2	-	-0.29
2026-05-18	ATRA	9.19	-106.2	-	-0.29
2026-05-19	ATRA	9.47	-106.2	-	-0.29
2026-05-20	ATRA	9.52	-106.2	-	0.29
2026-05-21	ATRA	9.41	-106.2	-	0.29
2026-05-22	ATRA	9.81	-284.2	-	-1.23
2026-05-26	ATRA	9.59	-284.2	-	-1.23
2026-05-27	ATRA	10.62	-284.2	-	-1.23
2026-05-28	ATRA	11.27	-284.2	-	-1.23
2026-05-29	ATRA	10.48	-284.2	-	-1.23
2026-06-01	ATRA	10.27	-100.0	-	-1.23
2026-06-02	ATRA	9.89	-100.0	-	-1.23
2026-06-03	ATRA	9.64	-100.0	-	-1.23
2026-06-04	ATRA	10.32	-100.0	-	-1.23
2026-06-05	ATRA	10.01	-100.0	-	-1.23
2026-06-08	ATRA	9.69	-100.0	-	-1.23
2026-06-09	ATRA	9.83	-100.0	-	-1.23
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-05-11	ATRA	-2.55	1.71	6.28
2026-05-12	ATRA	3.09	1.71	6.05
2026-05-13	ATRA	3.09	1.71	6.05
2026-05-14	ATRA	3.09	1.71	6.05
2026-05-15	ATRA	2.91	1.71	5.72
2026-05-18	ATRA	2.91	0.84	5.25
2026-05-19	ATRA	3.36	0.84	5.25
2026-05-20	ATRA	3.52	0.84	5.25
2026-05-21	ATRA	3.26	0.84	5.25
2026-05-22	ATRA	3.26	0.84	5.25
2026-05-26	ATRA	3.27	1.44	5.14
2026-05-27	ATRA	3.40	1.44	5.14
2026-05-28	ATRA	3.40	1.44	9.18
2026-05-29	ATRA	3.40	1.44	9.18
2026-06-02	ATRA	3.40	1.53	9.18
2026-06-03	ATRA	3.40	1.53	9.18
2026-06-04	ATRA	3.40	1.53	9.18
2026-06-05	ATRA	3.40	1.53	9.18
2026-06-08	ATRA	3.40	1.01	9.18
2026-06-09	ATRA	3.40	1.01	9.18
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.35

Avg. EPS Est. Next Quarter

-0.3

Insider Transactions

3.4

Institutional Transactions

1.01

Beta

0.13

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-99.2

Target Price

13.67

P/E

Forward P/E

10.92

PEG

P/S

3.8

P/B

P/Free Cash Flow

EPS

-0.88

Average EPS Est. Cur. Y

-1.23

EPS Next Y. (Est.)

1.64

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-40.91

Relative Volume

0.05

Return on Equity vs Sector %

-2.1

Return on Equity vs Industry %

14.1

EPS 1 7Days Diff

-0.9

EPS 1 30Days Diff

-0.94

EBIT Estimation

◆ ATRA Healthcare

$9.77

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

8/20

Pullback

8/25

Volume

11/15

Valuation

15/20

TP/AR

1/10

Options

0/10

RSI

56.6

Range 1M

56.8%

Sup Dist

4.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

9/30

Estimates

3/20

Inst/Vol

7/15

Options

0/10

EPS Yr

-150.4%

EPS NY

169.1%

52W%

39%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +359.6% upside

Quality

6/30

Valuation

18/30

Growth

6/25

Stability

7/10

LT Trend

3/5

Upside

+359.6%

Quality

Atara Biotherapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 14

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

ATRA

Latest News

—

Caricamento notizie per ATRA…

stock quote shares ATRA – Atara Biotherapeutics, Inc. Stock Price stock today

news today ATRA – Atara Biotherapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ATRA – Atara Biotherapeutics, Inc. yahoo finance google finance

stock history ATRA – Atara Biotherapeutics, Inc. invest stock market

stock prices ATRA premarket after hours

ticker ATRA fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ATRA

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y